This discussion emphasizes practical implementation. Freedland outlines how urologists and medical oncologists can collaborate to ensure timely therapy initiation and shares insights into patient- and ...
Nanopath's assay for cUTIs has received FDA breakthrough device designation, indicating its potential to significantly advance UTI diagnosis. The assay aims to deliver molecular results in 15 minutes, ...
The discussion opens with an overview of the evolving management of high-risk non–muscle invasive bladder cancer (NMIBC) and introduces the session’s goals of reviewing the treatment landscape, recent ...
Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...
Fast track designation accelerates development of [68Ga]Ga-DPI-4452 for ccRCC detection, enhancing FDA engagement and review processes. ITM-94, a gallium-68-radiolabeled PET agent, forms a theranostic ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...
Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation. In this video, urologist Jonathan Henderson, MD, of Arkansas Urology in Little Rock, reflects on ...
The government shutdown affects urology practices through halted CMS policy work and temporary Medicare payment disruptions. Expiration of Medicare telehealth flexibilities impacts rural and ...
The Avvio ELS has received FDA breakthrough device designation, enhancing its development and review process for treating ureteral stones. The system uses microbubble enhanced acoustic cavitation ...
177Lu-PSMA-617 addition to ADT and ARPI significantly improved rPFS in PSMA-positive mHSPC patients, with consistent benefits across subgroups. The PSMAddition trial showed a trend toward improved ...
The gemcitabine intravesical system offers localized chemotherapy delivery, providing a promising option for patients who have failed previous treatments. Successful implementation of new therapies ...
TRAVERSE trial showed no increase in MACE with testosterone therapy, improving sexual function and depression symptoms without affecting diabetes or prostate cancer outcomes. T4DM trial found a 13% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback